The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent
nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations …

Conventional therapy for acute myeloid leukemia is composed of remission induction with
cytarabine-and anthracycline-containing regimens, followed by consolidation therapy …

PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-
AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients …

Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …

Abstract Nucleophosmin 1 (NPM1) is a nucleus-cytoplasmic shuttling protein which is
predominantly located in the nucleolus and exerts multiple functions, including regulation of …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults that affects the
myeloid lineage. The recent advances have upgraded our understanding of the cytogenetic …

Simple Summary Venetoclax has proven to be a promising therapy for newly diagnosed,
relapsed and refractory AML patients ineligible for induction chemotherapy. Current ongoing …

Simple Summary Acute myeloid leukemia (AML) is one of the most common types of
leukemia in adults, with an average first diagnosis at age 68, and has historically carried …

Simple Summary The association of venetoclax (VEN) with hypomethylating agents (HMAs)
such as azacitidine (AZA) and decitabine (DECI) significantly improved the outcome of …

Background Venetoclax in combination with hypomethylating agents (HMA) is
revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large …